Evaluation of the Effects of 'High-Flow Nasal Cannula Oxygenation' Therapy on Vital Signs in Infants Diagnosed as Severe Acute Bronchiolitis Who Are Unresponsive to Conventional Therapy

• Main Authors: Mücahit Koçoğlu (Author), Ali Güngör (Author), Başak Yalçın Burhan (Author), Cüneyt Karagöl (Author), Alkım Öden Akman (Author)
• Format: Book
• Published: Galenos Publishing House, 2020-08-01T00:00:00Z.
• Subjects: article
• Online Access: Connect to this object online.
• Notes: 2822-4469; 10.5222/buchd.2020.33600
• Keywords: acute bronchiolitis; high-flow nasal cannula oxygenation; respiratory distress; pediatric intensive care; Pediatrics; RJ1-570
• Source: Journal of Behçet Uz Children's Hospital, Vol 10, Iss 2, Pp 190-196 (2020)

INTRODUCTION: High-flow nasal cannula oxygenation (HFNC) therapy is reported to provide a significant improvement in vital findings in pediatric patients who develop respiratory distress at acute bronchiolitis follow up. In our study, we aimed to evaluate the effects of HFNC therapy on vital findings in infants diagnosed severe acute bronchiolitis and also, we compared the mean duration and the number of hospitalizations of these patients in the intensive care unit with the period where HFNC was not available in our center. METHODS: This observational, single center study included patients (1-24 months) diagnosed with severe acute bronchiolitis who were administered HFNC therapy (1-2 L/kg/min with F&P Airvo 2TM optiflow device) between October 2017 and March 2018. Duration of hospitalization, respiratory and heart rate, blood pressure, and saturation of oxygen change values at 1st, 6th, 12th, and 24th hours of HFNC therapy were evaluated. Results: A total of RESULTS: A total of 41 patients was included in the study, 66% (n=27) were boys, the mean age was 7.5+-5.6 months, and the mean body weight was 7.5+-2.2 kilograms. Of all patients, 32 (78%) were followed up in the ward, and 9 (22%) were transferred to pediatric intensive care unit. Heart and respiratory rates were significantly decreased and saturation of oxygen was significantly increased at 1st, 6th, 12th, and 24th hours. No significant difference was found in the duration of hospitalization compared to the period where HFNC was not available.mpared to the period where HFNC was not available. DISCUSSION AND CONCLUSION: In our study, HFNC therapy significantly decreased respiratory and heart rate, and significantly improved SpO2. Our data about efficacy of HFNC therapy should be evaluated with multicenter studies.